Sun Pharmaceutical Business Intelligence Report
Sun Pharmaceutical Business Intelligence Report
Executive Cockpit
Latest Quarterly Earnings Summary
Loading latest quarter…
You're viewing a short preview. The full Business Intelligence Report covers 20+ in-depth sections.
AI Summary
Sun Pharmaceutical Industries is India's largest pharmaceutical company, evolving from a generic powerhouse to a global specialty player. The 10-year trajectory reflects a significant transformation where the company navigated intense US generic pricing pressures by pivoting toward high-margin specialty products in dermatology and ophthalmology. With a market cap of over ₹4.3 lakh crore, the company maintains a dominant 8%+ market share in India and a robust global manufacturing footprint. Financial performance has accelerated in the last 5 years, with profit growth of 17% CAGR outpacing…
Key Changes in FY2026
Sun Pharma has undergone a significant transformation from a pure-play generic and API player into a global specialty pharmaceutical powerhouse. The last decade saw the strategic shift toward high-margin chronic segments and complex generics, reducing dependence on volatile acute medications. The evolution into 'Specialty' (Dermatology, Ophthalmology, Onco-dermatology) has been the cornerstone of its recent growth, necessitating increased R&D and specialized field forces. Geographically, India and Emerging Markets now provide a robust floor, while the US business has matured into a specialty-focused operation. Digital transformation and premiumization of the India portfolio have further bolstered margins. This progression indicates a successful move up the value chain from commodity-like…
Management Commentary
Led by Dilip Shanghvi, the management team is regarded as one of the most astute in the Indian pharmaceutical sector. They have demonstrated foresight in moving away from the 'commodity generic' trap before many peers, focusing instead on complex generics and specialty medicines. Communication via analyst calls is transparent, focusing on long-term clinical trial outcomes and geographic expansion rather than short-term price fluctuations. Management has successfully integrated large-scale acquisitions (Ranbaxy) and managed complex US FDA regulatory hurdles across dozens of facilities. The transition toward professional management while maintaining founder vision is evident.
Financial Highlights
Sun Pharma's financial health is characterized by improving operating margins (now 27-30%) and consistent revenue growth. Over the last decade, sales grew at a 7% CAGR, but the most recent 5-year CAGR of 12% highlights a successful strategic pivot. The shift toward specialty products has stabilized margins that were previously volatile during the US generic commoditization cycle. Net profit margin is healthy at approximately 19-20%, while interest coverage ratios remain extremely high due to minimal borrowing. The increase in Sales from ₹27,392 Cr in 2015 to ₹58,462 Cr in 2026 (estimated) demonstrates a compounding machine at work. Capital efficiency has improved, with ROCE recovering from a low of 10% in 2018-2020 to over 20% currently.
Impact Balance
Balanced PictureTop 5 Positives
Strong EBITDA margins expanding to 30%
Critical · 83 · ProfitabilityAlmost debt-free balance sheet
High · 76 · SolvencyShift towards high-margin Specialty pharmaceuticals (26+ products)
High · 72 · ProfitabilityDouble-digit revenue CAGR over 5 years
Moderate · 58 · GrowthIndia's largest pharmaceutical company
Low · 42 · General
Top 5 Negatives
Significant spike in working capital days (185 days)
High · 79 · Cash FlowLow volume/inventory turns (363 days)
High · 66 · Cash FlowIntense competition in US generic market pricing
Moderate · 60 · Market PositionUS FDA regulatory scrutiny/warning letters on facilities
Moderate · 54 · Regulatory/MacroHigh R&D gestation periods for specialty molecules
Low · 40 · General
Inside the Full Intelligence Dossier · 20+ Sections
A preview of what the complete report analyses for this company.
About Sun Pharmaceutical's Annual Report & Financial Performance
The latest Sun Pharmaceutical annual report (FY2026) is the company's flagship annual disclosure, filed with NSE / BSE. It covers the full-year business review, management discussion & analysis, audited financial statements, the director's report, the corporate governance and auditor's reports, risk factors, capital allocation, subsidiaries, related-party transactions and ESG initiatives. This Business Intelligence Hub consolidates the official filings with AI-generated financial analysis so investors can see how revenue, operating margin, cash flow quality, capex, dividends, net debt and management outlook have changed — without reading the entire filing.
What this Sun Pharmaceutical research covers
- Fundamental & business analysis
- Financial statements & performance
- Management commentary & discussion
- Corporate governance & auditor report
- Cash flow analysis & capital allocation
- Valuation analysis & business quality
- Growth analysis & competitive position
- Risk, SWOT & moat analysis
- Quarterly earnings & conference-call summary
- Sector, industry & peer comparison
- Latest official company filings
- Business outlook & long-term growth
Sun Pharmaceutical — Frequently Asked Questions
Explore more Sun Pharmaceutical research
AI Top Insights — Premium
Unlock deeper AI Top Insights, advanced comparisons, downloadable reports and premium features.